Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent

Trial Profile

Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus First in man; Registrational; Therapeutic Use
  • Acronyms AURA; AURA extension; AURAext
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Nov 2017 Planned End Date changed from 1 Nov 2017 to 30 May 2018.
    • 18 Oct 2017 Results of genomic analysis (n=71), presented at the 18th World Conference on Lung Cancer.
    • 18 Oct 2017 Results of this and other trials (NCT01802632, NCT02094261 and NCT01544179) presented at the 18th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top